Ashwagandha for Perimenopause: Hormones, Sleep & HRT

Your body runs two hormonal control centres that share a single fuse box. One manages stress. The other manages reproduction. When stress affects the system — and for many women, it does — both may be impacted.

This is The Hormonal Seesaw — a concept that makes ashwagandha relevant to women's wellbeing in traditional medicine. Not because it adds hormones, but because it is traditionally used to support balance.

Three randomised controlled trials now test ashwagandha specifically in women: one for perimenopause symptoms (PMID: 34553463, n=100), one for menopausal symptoms (PMID: 41561822, n=60), and one for sexual function (PMID: 26504795, n=50). Four meta-analyses supply the mechanistic foundation. Here is what the evidence actually says — and where it runs out.

The Hormonal Seesaw: Why Stress Disrupts Women's Hormonal Balance Differently

Chronic stress may affect hormonal balance differently across sexes. In women, the HPA axis — the stress response system — interacts with the hypothalamic-pituitary-gonadal (HPG) axis that has been traditionally associated with oestrogen and progesterone production.

The relationship is complex. Cortisol and progesterone share a precursor hormone: pregnenolone. Under stress, the body may prioritise cortisol production over progesterone synthesis — a phenomenon sometimes called "pregnenolone steal" in traditional medicine. This has been theorised to contribute to changes in menstrual cycles and hormonal fluctuations during perimenopause.

A 2025 meta-analysis of 12 RCTs (PMID: 40746175, total n=488) confirmed that ashwagandha produces significant cortisol reduction compared to placebo. A separate 2024 meta-analysis (PMID: 39348746, total n=558) found consistent benefits for stress and anxiety measures across trials that included significant proportions of female participants.

However, here is the critical caveat: the 2025 cortisol meta-analysis (PMID: 40746175) found no significant effect on perceived stress despite reducing serum cortisol. Biological marker improvement did not translate to subjective stress improvement in pooled analysis. This matters — it means cortisol reduction alone may not resolve how stressed you feel.

What Three Women-Specific Trials Show

Perimenopause (PMID: 34553463, n=100)

This 2021 double-blind RCT remains an important women-specific trial. One hundred perimenopausal women received either 300 mg ashwagandha root extract twice daily or placebo for 8 weeks. The study reported changes in Menopause Rating Scale scores across various symptom categories.

This trial also measured hormones: the ashwagandha group showed changes in serum oestradiol and reductions in FSH and LH compared to placebo. This is one study that has observed hormonal changes in women taking ashwagandha that are the subject of ongoing research in traditional medicine.

Menopause (PMID: 41561822, n=60)

Published in January 2026, this newer RCT tested ashwagandha root extract in 60 menopausal women aged 45–55 for 56 days. Results included changes in MRS scores across psychological, somatic, and urogenital domains. Hormonal changes were also noted in this study as part of traditional understanding and ongoing research.

Sexual Function (PMID: 26504795, n=50)

A pilot study of 50 healthy women receiving 300 mg ashwagandha root extract twice daily for 8 weeks reported changes in Female Sexual Function Index scores across various parameters.

This is a pilot study — smaller sample, no hormonal measurements — but it contributes to traditional understanding and ongoing research on ashwagandha and women's wellbeing in herbal medicine.

"Ashwagandha root extract can be a safe and effective option to relieve mild to moderate climacteric symptoms during perimenopause in women." — Gopal et al. (2021), J Obstet Gynaecol Res

What the Evidence Does Not Show

Honesty about limitations is where real expertise lives. Here is what the current research does not demonstrate:

No PCOS-specific trials. The theoretical basis for ashwagandha in PCOS relates to cortisol's role in insulin resistance and androgen excess. This is biologically plausible. But no dedicated PCOS RCT has been completed. Do not take ashwagandha expecting it to resolve PCOS symptoms — the evidence simply is not there yet.

No female fertility outcomes. There is no human research suggests benefits for ashwagandha improving female fertility. The male fertility data exists (PMID: 35993457, systematic review of herbal medicines for male infertility, n=1,218), showing reduced FSH and improved semen parameters — but this does not translate to female fertility research.

No large oestrogen-level trials. While the perimenopause and menopause RCTs showed increased serum oestradiol, most studies on the mechanistic pathway were animal or in vitro models. The human evidence is limited to two trials of 100 and 60 participants respectively. Confirmation at scale is needed.

Stress vs stress perception gap. The 2025 cortisol meta-analysis (PMID: 40746175) found no significant effect on perceived stress despite reducing cortisol. This suggests ashwagandha's mechanism may work better at the biological level than the subjective experience level. A 2023 RCT (PMID: 37740662, n=60) in overweight middle-aged adults did not demonstrate significant stress reduction versus placebo on the primary Perceived Stress Scale outcome, although it did find significant fatigue reduction (p = 0.016).

Perimenopause and Menopause: Where the Evidence Is Strongest

Perimenopause is characterised by changes in oestrogen and progesterone levels, cortisol sensitivity, sleep patterns, and cognitive function. These are areas where ashwagandha has been traditionally used in herbal medicine to support general wellbeing.

A 2021 sleep meta-analysis (PMID: 34559859, 5 RCTs, total n=400) found ashwagandha significantly improved sleep quality, with effects more pronounced at doses used in studies of 600 mg or more and in treatment durations of 8 weeks or longer. For women navigating the sleep disruption of perimenopause, this is directly relevant.

Between the two dedicated menopause/perimenopause RCTs (PMID: 34553463 and PMID: 41561822), the evidence base for ashwagandha in menopausal symptom management is among the more researched for non-hormonal supplements in this population. It does not replace oestrogen. It does not address vasomotor symptoms through the same mechanism as hormone therapy. But for the stress, sleep, and psychological components, some traditional uses and studies have observed effects that are the subject of ongoing research.

Thyroid: A Bidirectional Consideration

A 2023 systematic review of herbal medicines for hypothyroidism (PMID: 37013429) identified ashwagandha as one of the botanicals with preliminary evidence for thyroid support, particularly in subclinical hypothyroidism. Thyroid dysfunction disproportionately affects women — approximately 1 in 8 will develop a thyroid condition in their lifetime.

However, this cuts both ways. Women with hyperthyroidism or autoimmune thyroid conditions (Hashimoto's or Graves' disease) should exercise caution. Ashwagandha's thyroid-stimulating potential means it is not suitable for everyone, and thyroid function should be monitored. See our detailed thyroid article for the full analysis.

From Our Formulations

Teelixir's ashwagandha is sourced from Rajasthan, India — the Di Tao (original source) region where Withania somnifera has been cultivated for centuries. We use 100% root material, never leaf. This matters because the clinical trials showing benefits for women (PMID: 34553463, 41561822, 26504795) all used root extract — not leaf, not root-and-leaf blends.

Our dual-extraction process uses both hot water and ethanol to capture the full withanolide spectrum that has been traditionally valued in herbal medicine. COA-verified minimum 2.5% withanolides at every batch. 10:1 extraction ratio. ACO certified organic. Third-party tested for heavy metals and microbial contamination.

This is a meaningful differentiator. Many commercial ashwagandha products use root-and-leaf blends (cheaper to produce) or single-extraction methods that miss ethanol-soluble compounds. The leaf contains higher concentrations of withaferin A, which has cytotoxic properties that may not be desirable for daily supplementation. Root-only extraction, as used in the clinical trials and in our product, avoids this concern.

What This Means in Practice

For stress-related hormonal disruption: If your primary driver is chronic stress affecting mood, sleep, and menstrual regularity, ashwagandha addresses the upstream cause. The cortisol-reduction benefit (confirmed across 12 RCTs, PMID: 40746175) creates space for the HPG axis to function more normally. You can start with 300 mg daily with food. This is most relevant for women in their late 20s to 40s under sustained occupational or personal stress.

For perimenopause and menopause: Ashwagandha is a reasonable complementary approach to managing the stress, sleep, and psychological dimensions of the menopausal transition. The evidence (PMID: 34553463, 41561822) supports 300 mg twice daily for at least 8 weeks. Consider combining with magnesium glycinate for sleep, and vitamin D if levels are low — both are common deficiencies in perimenopausal women. It is not a hormone replacement and should not be positioned as one.

For sexual wellbeing: The pilot study (PMID: 26504795) suggests 300 mg twice daily for 8 weeks may improve arousal, satisfaction, and sexual distress. Consider this alongside stress management — sexual dysfunction in women is frequently stress-driven, and addressing cortisol may be the mechanism.

For PCOS: The theoretical basis is plausible but the evidence is not there yet. General stress-reduction may provide some benefit, but direct PCOS outcomes are not established. This is unlikely to help as a standalone intervention for insulin resistance or androgen excess. Consult your healthcare professional for PCOS management.

For fertility: There is no human research suggests benefits for ashwagandha improving female fertility outcomes. If you are trying to conceive, do not rely on ashwagandha for this purpose. The stress-reduction effect may indirectly support reproductive health, but this is speculative.

When NOT to use ashwagandha: Pregnant women should avoid ashwagandha — uterine-stimulating effects are documented in traditional use, and no adequate human safety studies exist in pregnancy. Women with oestrogen-sensitive conditions (certain breast cancers, endometriosis) should seek professional advice before use. If you are taking hormonal contraceptives or hormone replacement therapy, consult your prescribing physician — the interaction evidence is limited but the hormonal interplay warrants professional guidance. If you have hyperthyroidism or Graves' disease, ashwagandha's thyroid-stimulating potential may not be appropriate for you.

Should YOU Take Ashwagandha?

Dosage Guidance for Women

For women new to ashwagandha, a traditional starting point is 300 mg daily with food. Assess response at 4 weeks before considering an increase to 600 mg if needed. Evening dosing may be preferred by some if sleep quality and relaxation are primary goals. With our 10:1 extract, half a teaspoon (approximately 300 mg) in warm milk, a smoothie, or golden milk is one approach. See our full dosage guide for more information.

Pair with magnesium for enhanced sleep benefits. Stack with reishi for deeper nervous system calming, or combine with tremella for combined stress-and-skin support — both are adaptogens with complementary mechanisms.

Frequently Asked Questions

Related reading: Ashwagandha Benefits: The Complete Guide · Ashwagandha for Anxiety and Stress · Ashwagandha for Sleep · Ashwagandha for Thyroid · Dosage Guide · Side Effects

Continue Your Research

• Ashwagandha for Hair and Skin: The Cortisol-Tissue Cascade
• Ashwagandha for Muscle Strength: The Anabolic Recovery Window Explained
• Ashwagandha for Gut Health: The Stress-Gut Axis Short-Circuit
• Ashwagandha vs Lion's Mane: The Body-Brain Divide
• Ashwagandha and Magnesium: Close the Dual Calm Gap
• Ashwagandha Research: What 1,584 Studies Tell Us

← Back to Ashwagandha Research Hub